digital currency group phone number- Top searches

SpaceX is valued at about $350 billion due to internal stock sales. According to an email sent to employees seen by the media, SpaceX and its investors have agreed to acquire the company's common stock of up to $1.25 billion at a price of $185 per share. This transaction values the rocket and satellite manufacturer owned by elon musk at about $350 billion.Sarah Friar, CFO of OpenAI: Corporate customers will pay (at least) thousands of dollars for using artificial intelligence (AI) tools. In the end, it will be reasonable.Morgan Asset Management: In 2025, there are sufficient reasons to continue to over-allocate US stocks. Sylvia Sheng, global multi-asset strategist of Morgan Asset Management, said that there are sufficient reasons to continue to over-allocate US stocks and increase exposure to small and medium-sized stocks. She pointed out that although the valuation may look high, it is expected that the profit growth of S&P 500 companies will continue. Sheng wrote that it is estimated that in 2025, the contribution of the six giants in the S&P 500 index to the profit growth of the other 494 stocks will be the same, and the profit growth of these six giants is expected to slow down from 40% in 2024 to 22%. In the international market, Morgan Asset Management continues to over-allocate Japanese stocks, and its quantitative model shows that the yield of Japanese stocks is attractive and the bottom-up profitability is strong.

Zhongzhou Special Materials: Shareholders have transferred and reduced their shares by more than 1%. Zhongzhou Special Materials announced that shareholders holding more than 5% have transferred their shares internally and reduced their shares by more than 1%. After the shareholder completed the internal transfer among the concerted parties, its shareholding ratio changed accordingly. At the same time, the shareholder reduced his shares through the secondary market, and the reduction ratio exceeded 1%. This share change is mainly for the adjustment of shareholding within the company's shareholders, and will not have a significant impact on the company's governance structure and daily operations.Sichuan issued 30-year ordinary special local bonds, with a scale of 35.4 billion yuan, an issue interest rate of 2.2000%, a marginal multiple of 1.58 times and an expected multiple of 2.19.The Bank of Korea increased its liquidity to try to calm the market sentiment, and the Bank of Korea increased its capital injection into the financial market, promising to provide "unlimited liquidity" after the political turmoil intensified. According to the website of the Bank of Korea, the liquidity increased by 14.1 trillion won ($9.8 billion) through repurchase operations last week. The scale of such operations was 18.5 trillion won in November and only 1.5 trillion won in October.

Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.Market information: Nissan will appoint JÉRÉMIE PAPIN as the chief financial officer on Wednesday.